JP4421779B2 - 改善された生産性を有するＦＡＰα−特異的抗体 - Google Patents

改善された生産性を有するＦＡＰα−特異的抗体 Download PDF

Info

Publication number
JP4421779B2
JP4421779B2 JP2000547119A JP2000547119A JP4421779B2 JP 4421779 B2 JP4421779 B2 JP 4421779B2 JP 2000547119 A JP2000547119 A JP 2000547119A JP 2000547119 A JP2000547119 A JP 2000547119A JP 4421779 B2 JP4421779 B2 JP 4421779B2
Authority
JP
Japan
Prior art keywords
antibody
human
cells
fap
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000547119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513556A5 (https=
JP2002513556A (ja
Inventor
ジョン エドワード パーク
チェーサ ピラール ガリン
ウーヴェ バンベルガー
ヴォルフガング ジェイ レーティッヒ
オリヴィエール レジェール
ジョージ ソルダーニャ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2002513556A publication Critical patent/JP2002513556A/ja
Publication of JP2002513556A5 publication Critical patent/JP2002513556A5/ja
Application granted granted Critical
Publication of JP4421779B2 publication Critical patent/JP4421779B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2000547119A 1998-04-30 1999-04-22 改善された生産性を有するＦＡＰα−特異的抗体 Expired - Lifetime JP4421779B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98107925.4 1998-04-30
EP98107925A EP0953639A1 (en) 1998-04-30 1998-04-30 FAPalpha-specific antibody with improved producibility
PCT/EP1999/002711 WO1999057151A2 (en) 1998-04-30 1999-04-22 FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY

Publications (3)

Publication Number Publication Date
JP2002513556A JP2002513556A (ja) 2002-05-14
JP2002513556A5 JP2002513556A5 (https=) 2006-06-22
JP4421779B2 true JP4421779B2 (ja) 2010-02-24

Family

ID=8231860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000547119A Expired - Lifetime JP4421779B2 (ja) 1998-04-30 1999-04-22 改善された生産性を有するＦＡＰα−特異的抗体

Country Status (27)

Country Link
EP (2) EP0953639A1 (https=)
JP (1) JP4421779B2 (https=)
KR (1) KR100580936B1 (https=)
CN (1) CN1303430A (https=)
AR (1) AR016243A1 (https=)
AT (1) ATE356873T1 (https=)
AU (1) AU760305B2 (https=)
BG (1) BG65034B1 (https=)
BR (1) BR9910577A (https=)
CA (1) CA2327586C (https=)
CO (1) CO5050255A1 (https=)
DE (1) DE69935516T2 (https=)
EA (1) EA005401B1 (https=)
EE (1) EE200000642A (https=)
ES (1) ES2283114T3 (https=)
HU (1) HUP0101501A3 (https=)
ID (1) ID26555A (https=)
IL (1) IL138701A0 (https=)
NO (1) NO20005412L (https=)
NZ (1) NZ508456A (https=)
PL (1) PL358087A1 (https=)
SK (1) SK16192000A3 (https=)
TR (1) TR200003181T2 (https=)
UA (1) UA73276C2 (https=)
WO (1) WO1999057151A2 (https=)
YU (1) YU66300A (https=)
ZA (1) ZA200005506B (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP2003530092A (ja) * 2000-03-17 2003-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ヒトＦＡＰ−α−特異抗体
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
WO2004001004A2 (en) * 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006517802A (ja) * 2003-02-14 2006-08-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 外来性分子の一過性の発現もしくは安定な発現のための発現カセットおよび発現ベクター
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
AU2009258063B2 (en) 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
ES2473623T3 (es) * 2007-08-20 2014-07-07 Glaxo Group Limited Procedimiento de producción
ES2527649T3 (es) * 2007-12-10 2015-01-28 F. Hoffmann-La Roche Ag Panel de marcadores para el cáncer colorrectal
EP2071337A1 (en) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase as a marker for cancer
MX2010004671A (es) * 2007-12-10 2010-05-27 Hoffmann La Roche Seprasa como marcador para cancer.
EP2274333A4 (en) 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
CN107325182A (zh) 2008-04-02 2017-11-07 宏观基因有限公司 HER2/neu‑特异性抗体和其使用方法
KR20120112384A (ko) 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
HUE036077T2 (hu) * 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
LT3653644T (lt) * 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
CN105646710B (zh) * 2014-11-17 2020-08-25 四川科伦博泰生物医药股份有限公司 一种全人源化抗vegfr-2单克隆抗体及其制备方法
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
SG11201806419RA (en) * 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CN110526979A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN110526991A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN109053893B (zh) * 2018-08-15 2021-03-30 智享生物(苏州)有限公司 一种抗d-二聚体单克隆抗体及其制备方法
CN110882385B (zh) * 2018-09-07 2021-07-09 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN118406106A (zh) 2019-07-08 2024-07-30 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
IL289673B2 (en) 2019-07-08 2026-04-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and their use
JP7628111B2 (ja) 2019-09-03 2025-02-07 バイオ － テラ ソリューションズ、リミテッド 抗ｔｉｇｉｔ免疫阻害剤及び応用
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
EP4143239A4 (en) * 2020-04-30 2024-10-02 I-Mab Biopharma Co., Ltd. PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
EP4198051A4 (en) * 2020-08-11 2024-05-01 Kanaph Therapeutics Inc. FUSION PROTEIN WITH IL-12 AND ANTI-FAP ANTIBODIES AND USE THEREOF
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
KR20230129261A (ko) 2021-01-07 2023-09-07 쓰리비 파마슈티컬스 게엠베하 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도
WO2023031644A1 (en) 2021-08-31 2023-03-09 Full-Life Technologies Limited Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
US20250297032A1 (en) * 2021-12-30 2025-09-25 Concept To Medicine Biotech Co., Ltd. Human antibodies against fap-alpha
EP4578877A1 (en) 2022-08-03 2025-07-02 Nanjing Leads Biolabs Co., Ltd. Antibody fusion protein targeting fap and tgf-beta, and use thereof
US20260053923A1 (en) 2022-10-07 2026-02-26 Genethon Immunotherapy of Skeletal Myopathies Using ANTI-FAP CAR-T Cells
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
WO2025152756A1 (zh) * 2024-01-15 2025-07-24 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用
CN118496382B (zh) * 2024-05-22 2025-01-07 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用
CN118812715A (zh) * 2024-07-02 2024-10-22 国睿(广州)生物科技有限公司 一种靶向成纤维活化蛋白α的纳米抗体及其应用
CN119265201A (zh) * 2024-08-23 2025-01-07 中国人民解放军海军军医大学第一附属医院 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993005804A1 (en) * 1991-09-18 1993-04-01 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
ZA936260B (en) * 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
AU725609C (en) * 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
WO1997041244A1 (en) * 1996-05-01 1997-11-06 Genitope Corporation Vaccines for treatment of lymphoma and leukemia

Also Published As

Publication number Publication date
NO20005412L (no) 2000-12-06
CO5050255A1 (es) 2001-06-27
AU4032299A (en) 1999-11-23
EA200001023A1 (ru) 2001-06-25
SK16192000A3 (sk) 2001-04-09
ZA200005506B (en) 2002-05-14
EP0953639A1 (en) 1999-11-03
TR200003181T2 (tr) 2001-04-20
HUP0101501A3 (en) 2004-01-28
HUP0101501A2 (hu) 2001-08-28
IL138701A0 (en) 2001-10-31
CA2327586C (en) 2013-02-26
DE69935516T2 (de) 2008-01-31
UA73276C2 (en) 2005-07-15
KR100580936B1 (ko) 2006-05-17
NO20005412D0 (no) 2000-10-27
KR20010042826A (ko) 2001-05-25
BG65034B1 (bg) 2006-12-29
ES2283114T3 (es) 2007-10-16
AU760305B2 (en) 2003-05-15
AR016243A1 (es) 2001-06-20
EA005401B1 (ru) 2005-02-24
EE200000642A (et) 2002-04-15
WO1999057151A2 (en) 1999-11-11
NZ508456A (en) 2004-03-26
DE69935516D1 (de) 2007-04-26
JP2002513556A (ja) 2002-05-14
ID26555A (id) 2001-01-18
BG104828A (en) 2001-09-28
EP1098979B1 (en) 2007-03-14
PL358087A1 (en) 2004-08-09
YU66300A (sh) 2004-03-12
BR9910577A (pt) 2001-09-11
EP1098979A2 (en) 2001-05-16
CA2327586A1 (en) 1999-11-11
ATE356873T1 (de) 2007-04-15
CN1303430A (zh) 2001-07-11
WO1999057151A3 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
JP4421779B2 (ja) 改善された生産性を有するＦＡＰα−特異的抗体
US6410690B1 (en) Therapeutic compounds comprised of anti-Fc receptor antibodies
US7074909B2 (en) Antibodies
EP0721470B1 (en) Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
KR101048894B1 (ko) 항-인간 테나신 단클론 항체
KR20010043470A (ko) Ｃｄ23에 대한 항체, 이의 유도체 및 이들의 치료적 용도
US20230212273A1 (en) Chimeric antibodies for treatment of amyloid deposition diseases
SK281143B6 (sk) Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
WO2011071783A1 (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
JP7667857B2 (ja) 新規な腫瘍エンゲージャ治療剤の開発及び使用
KR100693260B1 (ko) 항혈전제 및 인간화 항-폰빌레브란트 인자 모노클로날 항체
JP2010503381A (ja) プロテアーゼ活性化受容体１（ｐａｒ１）のアンタゴニスト
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
WO2022194201A1 (zh) 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
CZ20004032A3 (cs) Zdokonalená produkce protilátek specifických pro FAP-alfa
KR20250028447A (ko) 신규 다중 특이적 종양 억제제의 개발 및 응용
KR20200088061A (ko) 혈관형성을조절하는인테그린에대한키메라성및인간화항체
HK40028231A (en) Chimeric antibodies for treatment of amyloid deposition diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091028

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091203

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121211

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131211

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term